Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Zogenix Slipped 14.9% in August

By Maxx Chatsko - Sep 10, 2018 at 12:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced and completed a share offering last month, but the timing worked out well.

What happened

Shares of Zogenix ( ZGNX -4.97% ) fell nearly 15% last month, according to data provided by S&P Global Market Intelligence. The pharma company announced it was issuing up to 6.9 million shares of common stock at $52 apiece. While Mr. Market wasn't thrilled with the dilution, the share offering was actually a pretty wise move. That's because it took advantage of a recent surge in the stock price to raise up to $359 million in gross proceeds.

So what

The extra cash will come in handy, as Zogenix is preparing to submit applications for regulatory approval of ZX008 in both the United States and Europe by the end of the year. The drug candidate delivered positive results in a second phase 3 trial in July -- the cause of the stock's recent jump -- demonstrating its potential to treat Dravet syndrome. The drug is also being prepared to begin a phase 3 trial for Lennox-Gastaut syndrome. Both diseases are forms of epilepsy.

An ascending graph drawn on a chalkboard that shows a sudden descent.

Image source: Getty Images.

The most recent results were glowing, which has been the case all along for ZX008. That has helped the drug candidate to earn orphan drug status, breakthrough status, and fast-track status from the U.S. Food and Drug Administration. It also bodes well for the drug's eventual marketing approval for treating Dravet syndrome, which is rare but has inadequate options for patients.

Now what

Zogenix has seen its market valuation climb more than 300% in the last year to around $1.6 billion in early September. That's not too surprising, as it looks increasingly likely that the company will get regulatory nods for ZX008. However, seeing that the drug is the only one in development at the company, investors don't have much clarity over the long-term direction of the pharma. Perhaps it will make an acquisition to stock its pipeline or seek to be acquired itself, but right now, investors might want to consider that there may not be much upside to the stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
ZGNX
$11.85 (-4.97%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.